Frederick S. vom Saal · Environmental Health Perspectives 2024 · expert commentary / policy perspective · n=?

The Conflict between Regulatory Agencies over the 20,000-Fold Lowering of the Tolerable Daily Intake (TDI) for Bisphenol A (BPA) by the European Food Safety Authority (EFSA)

Cited 53 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Expert commentary and regulatory critique without new empirical data

OpenAlex W4394603168 · doi:10.1289/ehp13812 · record verified 2026-08-29

What was done

This commentary examines the regulatory disagreement surrounding the European Food Safety Authority's (EFSA) 20,000-fold lowering of the tolerable daily intake (TDI) for bisphenol A (BPA). The authors analyze and critique the rationale used by the German Federal Institute for Risk Assessment (BfR) and the US Food and Drug Administration (FDA) to uphold higher TDI levels, proposing the collaborative CLARITY-BPA model to integrate academic research into regulatory chemical hazard identification.

What was found

The abstract reports no new empirical measurements, effect sizes, or experimental data. The authors state that EFSA lowered the BPA TDI by 20,000-fold using a systematic review integrating academic and guideline studies, support the European Commission's acceptance of this assessment, and argue that regulatory reliance solely on mid-twentieth-century Good Laboratory Practice (GLP) guideline protocols fails to capture harm demonstrated by academic research.

Why it matters

This article outlines key methodological disputes in chemical risk assessment regarding whether regulatory bodies should incorporate non-guideline academic research to evaluate endocrine disruptors. It supports lowering tolerable exposure limits and phasing out BPA and structurally similar substitutes in food-related applications.

Limits

This is a narrative policy commentary and expert opinion piece, not an empirical study or systematic review. It presents qualitative arguments without new toxicological, epidemiological, or clinical data.

Cited by